Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
We tend to think of COVID-19 as a respiratory illness. But, like many viruses, COVID can also affect your skin and cause ...
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
If you're being treated for hives, your physician will want to hear what you think about your treatment. Is it working? Are your symptoms improving, staying the same, or getting worse? You may be ...
And the term encompasses an entire category of well-known skin conditions. "This (link) is something that we've known about for, honestly, centuries," Gehlhausen says. Hives are an itchy skin rash ...
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...
The higher the score, the greater the impact of hives. The Dermatology Life Quality Index or DLQI is another questionnaire used to evaluate the impact of skin disease, because patients with other ...
Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and ...